PL336304A1 - 5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds and their application as adenosine kinase inhibitors - Google Patents

5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds and their application as adenosine kinase inhibitors

Info

Publication number
PL336304A1
PL336304A1 PL98336304A PL33630498A PL336304A1 PL 336304 A1 PL336304 A1 PL 336304A1 PL 98336304 A PL98336304 A PL 98336304A PL 33630498 A PL33630498 A PL 33630498A PL 336304 A1 PL336304 A1 PL 336304A1
Authority
PL
Poland
Prior art keywords
aminopyrido
disubstituted
application
kinase inhibitors
pyrimidine compounds
Prior art date
Application number
PL98336304A
Inventor
Shripad S Bhagwat
Chih-Hung Lee
Marlon D Cowart
Jeffrey Mckie
Anne Laure Grillot
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PL336304A1 publication Critical patent/PL336304A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
PL98336304A 1997-04-16 1998-04-14 5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds and their application as adenosine kinase inhibitors PL336304A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83821697A 1997-04-16 1997-04-16
PCT/US1998/007207 WO1998046605A1 (en) 1997-04-16 1998-04-14 5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds and their use as adenosine kinase inhibitors

Publications (1)

Publication Number Publication Date
PL336304A1 true PL336304A1 (en) 2000-06-19

Family

ID=25276561

Family Applications (1)

Application Number Title Priority Date Filing Date
PL98336304A PL336304A1 (en) 1997-04-16 1998-04-14 5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds and their application as adenosine kinase inhibitors

Country Status (18)

Country Link
EP (1) EP0989986A1 (en)
JP (1) JP2001520655A (en)
KR (1) KR20010006509A (en)
CN (1) CN1252070A (en)
AR (1) AR012436A1 (en)
AU (1) AU7108398A (en)
BG (1) BG103842A (en)
BR (1) BR9809055A (en)
CA (1) CA2286909A1 (en)
CO (1) CO4940446A1 (en)
HU (1) HUP0001434A3 (en)
IL (1) IL131618A0 (en)
NO (1) NO995036D0 (en)
PL (1) PL336304A1 (en)
SK (1) SK141799A3 (en)
TR (1) TR199902455T2 (en)
WO (1) WO1998046605A1 (en)
ZA (1) ZA983177B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023444A1 (en) * 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
HU229604B1 (en) 2001-02-12 2014-02-28 Hoffmann La Roche 6-substituted pyrido-pyrimidines, process for their preparation and pharmaceutical compositions containing them
KR20040085151A (en) 2002-01-17 2004-10-07 뉴로젠 코포레이션 Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
DE10335183A1 (en) * 2003-07-30 2005-02-24 Bayer Cropscience Ag Fungicidal drug combinations
CN101243081A (en) * 2005-07-21 2008-08-13 霍夫曼-拉罗奇有限公司 Pyrido[2,3-d]pyrimidine-2,4-diamine compounds as PTP1B inhibitors
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
KR20080080395A (en) * 2005-12-21 2008-09-03 아보트 러보러터리즈 Anti-viral compounds
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
WO2009029632A1 (en) * 2007-08-27 2009-03-05 Helicon Therapeutics, Inc. Therapeutic isoxazole compounds
MX2010002098A (en) 2007-08-31 2010-03-30 Eisai R&D Man Co Ltd Polycyclic compound.
DE102007061764A1 (en) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellated cyanopyridines and their use
CN102333777B (en) * 2009-02-26 2014-06-25 卫材R&D管理有限公司 Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
WO2014055595A1 (en) 2012-10-05 2014-04-10 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitiors related applications
KR102375929B1 (en) 2016-03-31 2022-03-16 온크터널 테라퓨틱스, 인코포레이티드. Indoline analogs and uses thereof
CN110256420B (en) * 2019-05-07 2020-04-28 江西中医药大学 Tetrahydropyridopyrimidine derivatives, their preparation and use
CN110283171A (en) * 2019-07-17 2019-09-27 鼎泰(南京)临床医学研究有限公司 Compound of the one kind containing Pyridopyrimidine -4- amine structure, pharmaceutical composition and its application

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324731A (en) * 1989-02-14 1994-06-28 Amira, Inc. Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US6143749A (en) * 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds

Also Published As

Publication number Publication date
HUP0001434A3 (en) 2001-01-29
WO1998046605A1 (en) 1998-10-22
EP0989986A1 (en) 2000-04-05
CA2286909A1 (en) 1998-10-22
NO995036L (en) 1999-10-15
CO4940446A1 (en) 2000-07-24
CN1252070A (en) 2000-05-03
ZA983177B (en) 1999-01-22
NO995036D0 (en) 1999-10-15
BG103842A (en) 2000-06-30
AU7108398A (en) 1998-11-11
SK141799A3 (en) 2000-08-14
HUP0001434A2 (en) 2000-10-28
BR9809055A (en) 2000-08-08
TR199902455T2 (en) 2000-01-21
KR20010006509A (en) 2001-01-26
AR012436A1 (en) 2000-10-18
JP2001520655A (en) 2001-10-30
IL131618A0 (en) 2001-01-28

Similar Documents

Publication Publication Date Title
HUP0103472A3 (en) Pyrrolo[2,3-d]pyrimidine derivatives and pharmaceutical compositions containing the same
HRP20020798A2 (en) 5-ALKYLPYRIDO[2,3-d]PYRIMIDINES TYROZINE KINASE INHIBITORS
EP1043998A4 (en) USE OF PYRAZOLO 3,4-b] PYRIDINE AS CYCLIN DEPENDENT KINASE INHIBITORS
HK1036801A1 (en) Pyrrolo(2,3-d)pyrimidine compounds, composition and use there of
PL347020A1 (en) Pyrrolo[2,3d]pyrimidine compositions and their use
IL123581A0 (en) Pyrimidine derivatives as 5HT2c- receptor antagonists
AU1595197A (en) Novel pyrrolo{2,3-d}pyrimidines and their use as tyrosine kinase inhibitors
EG24399A (en) Pyrrolo[2,3-D]pyrimidine compounds
HK1069577A1 (en) Pyrazolo [4,3-D] pyrimidine derivatives
HUP0400692A3 (en) Substituted 7h-pyrrolo[2,3-d]pyrimidine derivatives, their use and pharmaceutical compositions containing them
IL125358A0 (en) 5H-thiazolo [3,2-a] pyrimidine derivatives
IL150545A0 (en) PYRIDO [2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS
PL336304A1 (en) 5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds and their application as adenosine kinase inhibitors
PL336262A1 (en) 6,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds
ZA983175B (en) 5, 6, 7-Trisubstituted-4-aminopyrido (2, 3-d) pyrimidine compounds